Analyzing Mateon Therapeutics (MATN) and Osiris Therapeutics (OSIR)

Osiris Therapeutics (OTCMKTS: OSIR) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Analyst Ratings

This is a breakdown of recent ratings for Osiris Therapeutics and Mateon Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osiris Therapeutics 0 0 0 0 N/A
Mateon Therapeutics 0 1 3 0 2.75

Mateon Therapeutics has a consensus price target of $1.75, suggesting a potential upside of 1,246.15%. Given Mateon Therapeutics’ higher probable upside, analysts plainly believe Mateon Therapeutics is more favorable than Osiris Therapeutics.

Institutional & Insider Ownership

0.3% of Osiris Therapeutics shares are owned by institutional investors. 44.6% of Osiris Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Mateon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Osiris Therapeutics and Mateon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osiris Therapeutics N/A N/A N/A
Mateon Therapeutics N/A -210.82% -175.67%

Earnings & Valuation

This table compares Osiris Therapeutics and Mateon Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osiris Therapeutics $59.87 million 3.45 -$1.78 million ($0.20) -29.95
Mateon Therapeutics N/A N/A -$13.65 million ($0.56) -0.23

Osiris Therapeutics has higher revenue and earnings than Mateon Therapeutics. Osiris Therapeutics is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Osiris Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Summary

Osiris Therapeutics beats Mateon Therapeutics on 7 of the 11 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

About Mateon Therapeutics

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Receive News & Ratings for Osiris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit